Stock picking
Magellan shares hit 10-year low as it continues to bleed funds
The fund manager’s share price plunged by almost a fifth on Friday after it said investors pulled another $2 billion from the company last month.
- by Millie Muroi
Latest
Opinion
Opinion
The $100b question: What’s ailing fund manager Magellan?
The hit from rock star stock pickers leaving the business is largely in the past. But the fund manager still faces a long road to regain investor confidence.
- by Clancy Yeates
The billion-dollar cheese: Should Bega be in investors’ shopping basket?
Bega Group makes some of Australia’s most beloved brands – but can it convince investors it’s a good buy, too?
- by Jessica Yun
Analysis
Investing
Five long-term stock picks from Australia’s biggest funds
Five fund managers at some of Australia’s largest investment firms have given their best stock picks for investors looking over the long term.
The Wrap: Tech and miners drag shaky ASX 1.1 per cent lower
The local sharemarket has slipped after Wall Street capped off a winning week with a sputtering finish.
- by Angus Dalton
Can Solomon Lew keep shooting the lights out at Premier?
With inflation soaring and tough times on the horizon, can Solomon Lew’s Premier Investments, which has the likes of Smiggle and Peter Alexander in its stable, keep performing?
- by Dominic Powell
McDonald’s in, Netflix out: The new face of Magellan reveals her picks
Magellan’s global equity fund, co-managed by Nikki Thomas, will be a key influence on whether the embattled money manager can turn things around.
- by Clancy Yeates
Shares take a hit, but is CSL still a good growth opportunity?
The nation’s most well-known biotech export is focused well beyond the pandemic, a period that gave it the kind of exposure money can’t buy.
- by Emma Koehn
Biden-approved: Should you invest in baby formula maker Bubs Australia?
Infant formula maker Bubs Australia has seen its share price soar since revealing a landmark US distribution deal, but does that make it a good investment?
- by Jessica Yun
Is Dolly Parton-backed biotech Moderna a good investment?
It’s the global vaccine maker that has delivered huge returns for early backers, but can Moderna continue its growth in a post-COVID world?
- by Emma Koehn
Bell Potter faces AUSTRAC probe over anti-money laundering compliance
The financial crimes watchdog has ordered external auditors to look into concerns the stockbroker may not be complying with anti-money laundering laws.
- by Charlotte Grieve
Original URL: https://www.smh.com.au/topic/stock-picking-1mp8